Pharmaceuticals News and Research

RSS

Horizon Discovery secures exclusive rights to human isogenic cell models

With the goal of developing new, more effective and personalized cancer treatments, Horizon Discovery, based in Cambridge, England, has secured from Case Western Reserve University exclusive rights to a panel of new human isogenic cell models developed by the laboratory of Zhenghe John Wang, assistant professor of genetics at the university's School of Medicine.

10 Dec 2010

PharmaDirections congratulates Orexigen on FDA Advisory approval for Contrave

PharmaDirections congratulates Orexigen Therapeutics on achieving FDA Advisory Board approval for their anti-obesity drug Contrave™. PharmaDirections is proud to have been Orexigen's pharmaceutical development partner and to have developed and produced the first Contrave™ product to undergo full clinical development.

10 Dec 2010

Clearance of plaque-forming substance is impaired in Alzheimer's disease

"Clearance is impaired in Alzheimer's disease," says Randall Bateman, MD, assistant professor of neurology at Washington University School of Medicine in St. Louis.

10 Dec 2010

Nacalai to distribute Techulon's Glycofect Transfection Reagent platform products in Japan

Techulon Inc., an early stage life sciences company has signed an agreement with Nacalai USA, Inc. and its parent company Nacalai Tesque, Inc. for distribution of its Glycofect Transfection Reagent platform products in Japan. Glycofect is a polymeric transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used by government, university and corporate laboratories around the world for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.

9 Dec 2010

Genetic Immunity to present DermaVir and DermaPrep transdermal delivery system at HIV DART 2010 conference

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week's HIV DART 2010 conference, "Frontiers in Drug Development for Antiretroviral Therapies," in Los Cabos, Mexico. The conference brings international researchers together to discuss the latest developments in the fight against HIV/AIDS.

9 Dec 2010

Clarient introduces Mammostrat test to quantify likelihood of breast cancer recurrence

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of Mammostrat, a patented, novel test designed to help quantify the likelihood of recurrence of breast cancer following surgery and initial treatment.

9 Dec 2010

Zealand receives EUR 500,000 milestone payment from Helsinn Healthcare for ZP1846 development program

Zealand Pharma, a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs that recently listed on NASDAQ OMX, today announces the receipt of a EUR 500,000 (DKK 3.73 million) milestone payment as part of its license agreement with Helsinn Healthcare for the development of ZP1846 for the treatment of chemotherapy-induced diarrhoea. This milestone payment has no impact on the Company's outlook for 2010.

9 Dec 2010

Results of proteomics study performed utilizing plasma samples from ADNI now available

The Foundation for the National Institutes of Health's Biomarkers Consortium announced today that the results of a proteomics study performed utilizing plasma samples from the Alzheimer's Disease Neuroimaging Initiative are ready to be shared with scientists worldwide for further analysis.

9 Dec 2010

Weifang Shengtai holds unveiling ceremony for 'Joint University-Business Community Program' with HUT

Shengtai Pharmaceutical, Inc. announced today that Weifang Shengtai Pharmaceutical, the Company's subsidiary in Changle, Shandong, China ("the Shandong Subsidiary"), held an unveiling ceremony for the "Joint University-Business Community Program" between the Company's Shandong subsidiary and the Hubei University of Technology ("HUT") in Changle, Shandong, China on December 4, 2010.

9 Dec 2010

Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the presentation of data from its proof of concept study with lead CNS compound Serdaxin® at the 49th American College of Neuropsychopharmacologists (ACNP) Annual Meeting, held in Miami Beach, FL, December 5-9, 2010 at the Fountainbleau Resort.

9 Dec 2010

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.

9 Dec 2010

Enbrel outperforms Humira in treating newly diagnosed RA patients: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen/Pfizer's Enbrel is the leading tumor necrosis factor -alpha inhibitor prescribed in newly diagnosed rheumatoid arthritis patients, outpacing Abbott's Humira in the first three lines of treatment.

9 Dec 2010

Teva, Active Biotech report positive initial results from laquinimod Phase III study in multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in annualized relapse rate compared to placebo. Additional clinical endpoints, including significant reduction in disability progression, as measured by Expanded Disability Severity Scale (EDSS), were also achieved.

9 Dec 2010

Medisafe 1 Technologies demonstrates syringe locking device at Israel's National Ministry of Health

Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company conducted an official demonstration of its barcoded syringe locking device at Israel's National Ministry of Health.

9 Dec 2010

Media examines efforts to protect patients in Africa from counterfeit medications

HP and the African social enterprise mPedigree on Monday announced a new service that will enable patients in Ghana and Nigeria to verify the authenticity of their medications, Fast Company reports. "Counterfeit drugs are estimated to be a $75-billion-per-year business, [and are] implicated in the deaths of something like 700,000 people around the world annually," according to the article (Zax, 12/6).

9 Dec 2010

New technique jumpstarts growth of nerve fibers to reverse stroke damage

A new technique that jumpstarts the growth of nerve fibers could reverse much of the damage caused by strokes, researchers report in the Jan. 7, 2011 issue of the journal Stroke.

9 Dec 2010

DPT granted FDA approval to manufacture Collagenase SANTYL Ointment for wound care

DPT Laboratories, Ltd., a pharmaceutical contract development and manufacturing organization, announced today that it received FDA approval to manufacture commercial supplies of a leading sterile ointment for wound care at its Center of Excellence for Sterile & Specialty Products in Lakewood, N.J. Beginning this month, Healthpoint will ship commercial lots of Collagenase SANTYL® Ointment produced at DPT's Lakewood facility to its North American customers.

9 Dec 2010

NIH to create new translational science center

National Institutes of Health (NIH) Director Francis Collins on Tuesday announced the agency is moving forward on plans to create a new research center focused on translational science, after NIH's advisory board voted to create the new center, Science's "Science Insider" blog reports (Kaiser, 12/7).

9 Dec 2010

India, EU trade agreement will not restrict ability for India's pharmaceutical firms to export generic drugs, official says

"India and the European Union (EU) have agreed that the comprehensive bilateral trade agreement being negotiated by the two will not result in an intellectual property regime that restricts the ability of Indian pharmaceutical firms to export generic or off-patent drugs by being far more stringent than the TRIPS [Trade-Related Aspects of International Property Rights] regime of the World Trade Organization," LiveMint.com reports in an article that describes recent debates over the agreement.

9 Dec 2010

Three drug companies to pay $421 million in fraud settlement

Los Angeles Times: Three pharmaceutical firms — Roxane, Abbott Laboratories and B. Braun Medical — "agreed to pay more than $421 million to settle claims of defrauding Medicare and Medicaid — the latest in a string of large healthcare fraud settlements announced by the Justice Department. The drug companies charged one set of prices to doctors and pharmacies but reported another set of inflated figures that were used as benchmarks by government insurers reimbursing healthcare providers, authorities said" (Zajac, 12/8).

9 Dec 2010

Pharmaceuticals News and Research

Horizon Discovery secures exclusive rights to human isogenic cell models

PharmaDirections congratulates Orexigen on FDA Advisory approval for Contrave

Clearance of plaque-forming substance is impaired in Alzheimer's disease

Nacalai to distribute Techulon's Glycofect Transfection Reagent platform products in Japan

Genetic Immunity to present DermaVir and DermaPrep transdermal delivery system at HIV DART 2010 conference

Clarient introduces Mammostrat test to quantify likelihood of breast cancer recurrence

Zealand receives EUR 500,000 milestone payment from Helsinn Healthcare for ZP1846 development program

Results of proteomics study performed utilizing plasma samples from ADNI now available

Weifang Shengtai holds unveiling ceremony for 'Joint University-Business Community Program' with HUT

Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Enbrel outperforms Humira in treating newly diagnosed RA patients: Report

Teva, Active Biotech report positive initial results from laquinimod Phase III study in multiple sclerosis

Medisafe 1 Technologies demonstrates syringe locking device at Israel's National Ministry of Health

Media examines efforts to protect patients in Africa from counterfeit medications

New technique jumpstarts growth of nerve fibers to reverse stroke damage

DPT granted FDA approval to manufacture Collagenase SANTYL Ointment for wound care

NIH to create new translational science center

India, EU trade agreement will not restrict ability for India's pharmaceutical firms to export generic drugs, official says

Three drug companies to pay $421 million in fraud settlement

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence